Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

lesinurad Oral Tablet [Zurampic]

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Up to 90% of gout patients experience low uric acid (UA) excretion rather than high UA production. The selective UA reabsorption… Expand
Is this relevant?
Review
2017
Review
2017
Lesinurad (Zurampic®) is an oral selective inhibitor of the URAT1 and OAT4 uric acid (UA) transporters of the kidney, via which… Expand
  • table 1
  • figure 1
Is this relevant?
2016
2016
BACKGROUND Excess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most… Expand
Is this relevant?
Review
2016
Review
2016
Lesinurad (ZURAMPIC®) is an oral urate–anion exchanger transporter 1 (URAT1) inhibitor developed by Ardea Biosciences (a… Expand
Is this relevant?
2016
2016
BackgroundExcess body burden of uric acid promotes gout. Diminished renal clearance of uric acid causes hyperuricemia in most… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • table 2
Is this relevant?